載入中
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
前收盤價
US$3.51
−US$0.12 · -3.31%
盤中時間採用ET。市場資料可能有所延遲。
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
日內區間
目前US$3.51
52週區間
目前US$3.51
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
48
合理估值
情緒
43
多空交錯
風險
96
極高風險
動能
24
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
日內區間
目前US$3.51
52週區間
目前US$3.51
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 研究與開發 | 223.7萬 USD | 33.5萬 USD | 56.7萬 USD | 111.6萬 USD |
| 銷售、一般及管理費用 | 266.7萬 USD | 74.3萬 USD | 58萬 USD | 92.6萬 USD |
| 營業費用 | 490.4萬 USD | 107.8萬 USD | 114.7萬 USD | 204.2萬 USD |
| 利息支出 | — | 2.9萬 USD | 4.9萬 USD | 1.8萬 USD |
| 營業利益 | −490.4萬 USD | −107.8萬 USD | −114.7萬 USD | −204.2萬 USD |
| 淨利 | −585.6萬 USD | −153.2萬 USD | −105.1萬 USD | −171.1萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$22.00
上漲空間 526.78%AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
